Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

Pharmacogenetics

Volumn 12, Issue 2, 2002, Pages 111-119

  Shon, Ji Hong ^a   Yoon, Young Ran ^a   Kim, Kyoung Ah ^a   Lim, Young Chae ^a   Lee, Kwang Jae ^a   Park, Ji Young ^a   Cha, In June ^a   Flockhart, David A ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

CYP2C19; CYP2C9; Genetic polymorphism; Pharmacodynamics; Pharmacokinetics; Tolbutamide

Indexed keywords

4 HYDROXYTOLBUTAMIDE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; GLUCOSE; PLACEBO; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG RESPONSE; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; SINGLE-BLIND METHOD; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0036217595     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200203000-00005     Document Type: Article

References (33)

1. Comparative single dose kinetics and effects of four sulfonylureas in healthy volunteers
2. The use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
3. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
4. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations
5. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
6. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes
7. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide
8. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli
9. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
10. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
11. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
12. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments
13. Involvement of cytochrome P450 2C19 in methylhydroxylation of tolbutamide in vitro
14. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
15. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
16. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
17. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9
18. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
19. Frequency of cytochrome P450 CYP2C9 mutant alleles in a Korean population
20. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
21. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
22. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
23. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population
24. Simple high-performance liquid chromatographic method for the determination of tolbutamide and its metabolites in human plasma and urine using photodiode-array detection
25. Pharmacogenetics of tolbutamide metabolism in humans
26. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
27. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
28. Interethnic differences in omeprazole metabolism in two S-mephenytoin hydroxylation phenotypes studies in Caucasians and Orientals
29. Genetic analysis of CYP2C9 polymorphism in a Japanese population
30. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele
31. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
32. Gender effects in pharmacokinetics and pharmacodynamics
33. Gender-related differences in pharmacokinetics and their clinical significance